Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

OncoSec Medical To Present At Upcoming Investor Conference

Biopharmaceutical company OncoSec Medical (OTC:ONCS) said Thursday that its president and CEO, Punit Dhillon, will speak at the VC in the OC investor conference in California, on May 15th.

The conference will take place at the Hyatt Regency Huntington Beach, in Huntington Beach, California. OncoSec Medical will speak at 4:25 pm (NYSE:PT).

VC in the OC is the first of two signature events held each year by OCTANe, a not-for-profit organization composed of technology executive leaders, entrepreneurs, investors, and other capitalists and advisors in the Orange County area.

This year's event will feature 14 investment presentations that are seeking seed, series A, or later stage venture capital investment.

OnoSec Medical is an emerging drug-medical device company focused on the design, development, and commercialization of medical approaches for the treatment of solid cancers.

In April, OncoSec unveiled positive interim data from a phase IV trial testing its OMS (OncoSec Medical System) ElectroChemotherapy treatment in Europe.

The cancer therapy company uses its OMS electroporation delivery system that applies short electric pulses to cells, causing the opening of pores in the cell membrane, and allowing for the efficient and safe delivery of immunotherapy or chemotherapy agents to treat a range of solid tumour cancers.

The OMS electroporation system has proven to enhance cellular uptake, effectively treating cancerous cells while sparing surrounding healthy tissue cutting through the toxic side effects of current available treatment options like chemotherapy, radiation and surgery.

The company announced last month interim analysis of data from 81 subjects in a phase IV study of patients with primary (new) and locally recurrent squamous cell carcinoma of the head and neck.

The patients were treated with OMS ElectroChemotherapy, with the study showing the therapy's ability to provide local tumour control and quality of life outcomes that "compared favourably" to standard outcomes associated with surgery, the company said.

In the interim analysis, local tumor control was achieved in 46 of 49, or 94 percent, of primary tumors and 12 of 21, or 57 percent, of recurrent tumors.